Transplant Immunology
Overview of Transplantation
Purpose of Transplants:
Restore function when an organ or tissue is irreparably damaged by disease or injury.
Address congenital absence or defects of organs or tissues.
Graft: Healthy tissue or organ transplanted.
Donor: Individual providing the tissue or organ.
Recipient: Individual receiving the tissue or organ.
Classification of Transplants
Immunological-Genetic & Antigenic Relationship:
Autograft: Transplant from self.
Syngeneic (Isograft): Between genetically identical individuals, e.g., identical twins.
Allograft (Homograft): Between individuals of the same species with different genetic makeup.
Xenograft (Heterograft): Between different species.
By Organ/Tissue:
Kidney, heart, skin transplants, etc.
Immunology and Transplantation
Success Factors:
Genetic match between donor and recipient.
Critical genes include those for ABO blood group antigens and MHC receptors.
Major Histocompatibility Complex (MHC)
HLA Gene Matching:
Close matching of HLA genes increases transplant success.
HLA genes have high genetic variability, making matching difficult.
HLA complex includes over 200 genes on chromosome 6, divided into Class I, II, and III.
Genetic Diversity:
HLA complex is highly diverse; over 5000 HLA alleles.
Each individual has 12 HLA class I and II genes (6 from each parent).
HLA Testing
Testing Types:
HLA gene typing of donor and recipient.
HLA antibody screening of the recipient.
Lymphocyte cross-matching to detect recipient antibodies against donor lymphocytes.
Recognition of Alloantigens by T Cells
Mechanisms:
Direct Recognition: Recipient's T cells recognize allogeneic MHC molecules directly.
Indirect Recognition: Recipient's antigen-presenting cells process and present donor MHC molecules.
Activation and Effector Functions of Alloreactive T Lymphocytes
T Cell Response:
Initiated in lymph nodes draining the graft.
CD4+ T Cells: Produce cytokines leading to graft inflammation.
CD8+ T Cells: Differentiate into cytotoxic T lymphocytes (CTLs) that kill graft cells.
Alloreactive B Cells and Alloantibodies
Role of Antibodies:
Donor-specific antibodies contribute to rejection.
Antibodies produced via T cell-dependent activation of B cells.
Target both class I and II MHC proteins and non-HLA alloantigens.
Cause damage through complement activation and Fc receptor-mediated cell activation.
Types of Allograft Rejection
Hyperacute Rejection:
Occurs within minutes to 24 hours.
Mediated by preexisting antibodies against ABO blood group antigens or MHC molecules.
Results in vascular thrombosis and type II hypersensitivity reaction.
Acute Rejection:
Occurs 1 week to several months post-transplant.
Mediated by T cells (cell-mediated) and B cells (antibody-mediated).
Cell-mediated: CTLs attack graft cells.
Antibody-mediated: Antibodies cause vasculitis and lymphocytic infiltrates.
Type IV hypersensitivity reaction.
Chronic Rejection:
Occurs months or years post-transplant.
Involves both cellular and humoral immune responses.
Characterized by arterial occlusion and ischemic damage.
Mediated by cytokines causing smooth muscle proliferation and tissue fibrosis.
Type II and type IV hypersensitivity reaction
Methods to Reduce Allograft Immunogenicity
Donor-Recipient Matching:
ABO blood group antigen compatibility.
MHC allele matching, especially for kidney transplants.
Preformed antibody testing.
Immunosuppressive Drugs:
Used to inhibit or kill T lymphocytes and prevent graft rejection.
Hematopoietic Stem Cell (HSC) Transplantation
Purpose:
Treat diseases caused by defects in hematopoietic lineages.
HSCs obtained from donor blood post-treatment with colony-stimulating factors.
Graft Versus Host Reaction (GVHR):
Occurs when donor immune cells attack recipient tissues.
Requires graft with immunocompetent T cells and an immunocompromised host.
Acute GVHR occurs 7-30 days post-transplant.
Immunodeficiency Post-HSC Transplantation:
Recipients may struggle to regenerate a complete new lymphocyte repertoire.
Increased susceptibility to viral, bacterial, and fungal infections.